These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23300780)

  • 1. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.
    Krakstad C; Birkeland E; Seidel D; Kusonmano K; Petersen K; Mjøs S; Hoivik EA; Wik E; Halle MK; Øyan AM; Kalland KH; Werner HM; Trovik J; Salvesen H
    PLoS One; 2012; 7(12):e52795. PubMed ID: 23300780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.
    Byron SA; Gartside M; Powell MA; Wellens CL; Gao F; Mutch DG; Goodfellow PJ; Pollock PM
    PLoS One; 2012; 7(2):e30801. PubMed ID: 22383975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.
    Rudd ML; Price JC; Fogoros S; Godwin AK; Sgroi DC; Merino MJ; Bell DW
    Clin Cancer Res; 2011 Mar; 17(6):1331-40. PubMed ID: 21266528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
    Kang S; Seo SS; Chang HJ; Yoo CW; Park SY; Dong SM
    Int J Gynecol Cancer; 2008; 18(6):1339-43. PubMed ID: 18221484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.
    Cote ML; Atikukke G; Ruterbusch JJ; Olson SH; Sealy-Jefferson S; Rybicki BA; Alford SH; Elshaikh MA; Gaba AR; Schultz D; Haddad R; Munkarah AR; Ali-Fehmi R
    Int J Gynecol Cancer; 2012 Oct; 22(8):1367-72. PubMed ID: 23013731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
    Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
    Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.
    Urick ME; Rudd ML; Godwin AK; Sgroi D; Merino M; Bell DW
    Cancer Res; 2011 Jun; 71(12):4061-7. PubMed ID: 21478295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.
    Birkeland E; Wik E; Mjøs S; Hoivik EA; Trovik J; Werner HM; Kusonmano K; Petersen K; Raeder MB; Holst F; Øyan AM; Kalland KH; Akslen LA; Simon R; Krakstad C; Salvesen HB
    Br J Cancer; 2012 Dec; 107(12):1997-2004. PubMed ID: 23099803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: A proof-of-concept study.
    Mayo-de-Las-Casas C; Velasco A; Sanchez D; Martínez-Bueno A; Garzón-Ibáñez M; Gatius S; Ruiz-Miró M; Gonzalez-Tallada X; Llordella I; Tresserra F; Rodríguez S; Aldeguer E; Roman-Canal B; Bertran-Alamillo J; García-Peláez B; Rosell R; Molina-Vila MA; Matias-Guiu X
    Int J Cancer; 2020 Jul; 147(1):277-284. PubMed ID: 31953839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis.
    Georgieva IA; Mauerer A; Groesser L; Herschberger E; Aslanidis C; Dietmaier W; Landthaler M; Hafner C
    Am J Dermatopathol; 2014 Aug; 36(8):635-42. PubMed ID: 23739246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.
    Dobrzycka B; Terlikowski SJ; Mazurek A; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
    Folia Histochem Cytobiol; 2009; 47(1):65-8. PubMed ID: 19419940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
    Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S
    Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
    Garrido-Laguna I; Hong DS; Janku F; Nguyen LM; Falchook GS; Fu S; Wheler JJ; Luthra R; Naing A; Wang X; Kurzrock R
    PLoS One; 2012; 7(5):e38033. PubMed ID: 22675430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
    Cheung LW; Hennessy BT; Li J; Yu S; Myers AP; Djordjevic B; Lu Y; Stemke-Hale K; Dyer MD; Zhang F; Ju Z; Cantley LC; Scherer SE; Liang H; Lu KH; Broaddus RR; Mills GB
    Cancer Discov; 2011 Jul; 1(2):170-85. PubMed ID: 21984976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
    Berg A; Hoivik EA; Mjøs S; Holst F; Werner HM; Tangen IL; Taylor-Weiner A; Gibson WJ; Kusonmano K; Wik E; Trovik J; Halle MK; Øyan AM; Kalland KH; Cherniack AD; Beroukhim R; Stefansson I; Mills GB; Krakstad C; Salvesen HB
    Oncotarget; 2015 Jan; 6(2):1327-39. PubMed ID: 25415225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.
    Bozzao C; Varvara D; Piglionica M; Bagnulo R; Forte G; Patruno M; Russo S; Piscitelli D; Stella A; Resta N
    Int J Biol Markers; 2012 Dec; 27(4):e366-74. PubMed ID: 23125007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma.
    Bruckman KC; Schönleben F; Qiu W; Woo VL; Su GH
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Nov; 110(5):632-7. PubMed ID: 20813562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer.
    Ikeda Y; Oda K; Nakagawa S; Murayama-Hosokawa S; Yamamoto S; Ishikawa S; Wang L; Takazawa Y; Maeda D; Wada-Hiraike O; Kawana K; Fukayama M; Aburatani H; Yano T; Kozuma S; Taketani Y
    Int J Gynecol Cancer; 2012 Jun; 22(5):725-31. PubMed ID: 22635024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.